Literature DB >> 20003320

Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies.

Denis Malvy1, Khaled Ezzedine, Maria Mamani-Matsuda, Brigitte Autran, Hugues Tolou, Marie-Catherine Receveur, Thierry Pistone, Jérome Rambert, Daniel Moynet, Djavad Mossalayi.   

Abstract

BACKGROUND: Chikungunya fever is an emerging arboviral disease characterized by an algo-eruptive syndrome, inflammatory polyarthralgias, or tenosynovitis that can last for months to years. Up to now, the pathophysiology of the chronic stage is poorly understood. CASE
PRESENTATION: We report the first case of CHIKV infection with chronic associated rheumatism in a patient who developed progressive erosive arthritis with expression of inflammatory mediators and persistence of specific IgM antibodies over 24 months following infection.
CONCLUSIONS: Understanding the specific features of chikungunya virus as well as how the virus interacts with its host are essential for the prevention, treatment or cure of chikungunya disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20003320      PMCID: PMC2803790          DOI: 10.1186/1471-2334-9-200

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Chikungunya virus (CHIKV) is an enveloped positive-strand RNA alphavirus which can infect human epithelial and endothelial cells, fibroblasts or macrophages [1,2]. A CHIKV epidemic recently occurred on islands of the Indian Ocean in 2005 [3-5]. CHIKV infection may cause an algoeruptive syndrome with disabling joint pain and recurrent rheumatic manifestations [6-8]. Until now, it has been assumed that complete recovery occurs, even when symptoms are long lasting. Remarkably, despite the severity and duration of arthritis, articular destruction has been reported very rarely [9]. We report the case of a patient with CHIKV infection presenting with severe chronic rheumatism accompanied by progressive destructive arthritis and dysregulated expression of inflammatory mediators.

Case presentation

In November 2005, a 60-year-old French man living in La Réunion experienced an acute influenza-like illness with diffuse arthralgia affecting bilaterally the distal inter-phalangeal joints of the fingers and the toes with hand tenosynovitis. His past medical history was unremarkable with no family history of inflammatory rheumatism. Serology demonstrated the presence of anti-CHIKV IgM and confirmed the diagnosis of CHIKV infection. During the following months, the patient had persisting inflammatory arthralgia and joint stiffness which were not improved by symptomatic treatment. One year later, he developed refractory tenosynovitis in the wrists. On February 15, 2007, the patient returned to France and consulted in our department. He complained of persistent symmetrical inflammatory arthritis of the wrists with fixed oedema of the two hands predominating on the right. Hand synovitis of the extensors and the flexors of wrists and fingers were noted. Lymphocyte immunophenotyping showed an increased CD4 T-cell count at 1,18 × 109/L (63.5%) and an activated CD45/CD3 (-) T-cell count at 0.209 × 109/L (11.3%), and CD45/CD3 (+) at 0,119 × 109/L (6.4%). Serum immunoglobulin was normal, as were the C3 and C4 complement fractions. No markers of autoimmunity were found, notably anti-citrullin peptide antibodies, antinuclear antibodies or cryoglobulinemia. The HLA B27 gene was positive and HLA system class II genotyping revealed an HLA-DRB1.03.11 genotype. At the time of the consultation, serologic status for CHIKV antibodies was reevaluated using IgM-capture and an IgG-capture enzyme-linked immunoabsorbent assay with inactivated cell-culture-ground chikungunya virus and mouse anti-chikungunya hyperimmune ascitic fluid (Institut Pasteur, Lyon, France). Persistent specific anti-CHIKV IgM was detected in this late stage serum sample, collected 18 months after the infection, with optical density (OD) values of 1.47 for IgG and 0.81 for IgM. Testing for CHIKV RNA was negative [10]. Radiography of the hands and wrists showed a subchondral defect of the 2nd and 3rd right proximal interphalangeal finger joints as well as of the 3rd, 4th and 5th left distal interphalangeal joints. Magnetic resonance imaging (MRI) of the hands and wrists revealed marked bilateral periostal inflammation and oedematous carpitis (Fig 1A and 1B), with carpis synovitis (1C) and bone destruction in the left hand (1D) accompanied by intra-articular swelling (1D). Bone scintigraphy revealed diffuse inflammation of several joints, prominent in the right wrist (3rd metacarpo-phalangeal joint) (Fig 1E) and the left ankle (1F), as well as evolutive enthesopathy of the left calcaneum. Methotrexate (MTX) was initiated at the dose of 17.5 mg/week and four months later, dramatic improvement was observed in both the number and state of swollen and tender joints and in tendon involvement. At this time, MRI of the hands, wrists and feet showed reduced progression of erosion and a decrease in radiographic inflammation and oedematous damage compared to before treatment. Clinical and radiological improvement was maintained over 15 months. At this end-point, CHIKV antibody serology showed persistence of both specific IgM and IgG, with OD values of 0.60 and 0.32, respectively.
Figure 1

Magnetic resonance imaging (MRI) and bone scintigraphy of the hands and wrists of a 60-year-old man with chikungunya virus infection revealing. A. Arthritis of the 3rd metacarpo-phalangeal joint of the right hand with extensor tenosynovitis associated with intra-articular swelling (red arrow on axial section, time-resolved contrast-enhanced T1-weighted sequence after Gadolinium injection with fat suppression) B. Bilateral periostum inflammation and oedematous carpitis with synovitis predominating on the left hand (arrow on axial section, time-resolved-enhanced T2-weighted sequence with fat suppression) C. Asymmetric inflammatory carpitis with multiple synovitis of flexors of the left wrist (red arrows on axial section, time-resolved contrast-enhanced T1-weighted sequence after Gadolinium injection with fat suppression) D. Bone destruction on the left hand (red arrows on coronal section, time-resolved contrast-enhanced T1-weighted sequence with fat suppression) E. Bone scintigraphy of the wrists and hands showing an intense focus of technetium 99 m-labeled methylene disphosphonate tracer uptake, particularly in the right metacarpo-phalangeal wrist. F. Bone scintigraphy of the left foot showing an intense focus of technetium 99 m-labeled methylene disphosphonate tracer uptake, particularly in the left ankle.

Magnetic resonance imaging (MRI) and bone scintigraphy of the hands and wrists of a 60-year-old man with chikungunya virus infection revealing. A. Arthritis of the 3rd metacarpo-phalangeal joint of the right hand with extensor tenosynovitis associated with intra-articular swelling (red arrow on axial section, time-resolved contrast-enhanced T1-weighted sequence after Gadolinium injection with fat suppression) B. Bilateral periostum inflammation and oedematous carpitis with synovitis predominating on the left hand (arrow on axial section, time-resolved-enhanced T2-weighted sequence with fat suppression) C. Asymmetric inflammatory carpitis with multiple synovitis of flexors of the left wrist (red arrows on axial section, time-resolved contrast-enhanced T1-weighted sequence after Gadolinium injection with fat suppression) D. Bone destruction on the left hand (red arrows on coronal section, time-resolved contrast-enhanced T1-weighted sequence with fat suppression) E. Bone scintigraphy of the wrists and hands showing an intense focus of technetium 99 m-labeled methylene disphosphonate tracer uptake, particularly in the right metacarpo-phalangeal wrist. F. Bone scintigraphy of the left foot showing an intense focus of technetium 99 m-labeled methylene disphosphonate tracer uptake, particularly in the left ankle.

Immunological evaluation

T cell function was assessed using proliferation assays and ELISPOT quantification of interferon-γ (IFN-γ) production by T cells. No proliferative response or IFN-γ production could be detected in response to CHIKV antigens derived from an in-house preparation of β-propionolactone-inactivated virus (French Armed Forces Institute of Tropical Medicine, Marseilles, France). T cell viability was ascertained by concurrent detection in the same assays of T cells responding to candidin and herpes simplex virus-1 antigens tested as controls. Peripheral blood lymphocytes (PBL) from the patient and from three healthy control individuals were isolated and analysed at a transcriptomic level using real-time reverse transcriptase-polymerase chain reaction (PCR) to detect mRNA species encoding inflammatory mediators (RT2 Profiler™ PCR Array Human Inflammatory Cytokine and Receptors, SuperArray, Frederick, USA). Each PCR used the same quantity of total RNA from each cell culture and the absence of a signal after 35 PCR cycles was taken as the threshold for the mRNA not being detectable. These PCR analyses were completed by measurement of cytokine levels in the serum and in the 48 h PBL-derived supernatant. These analyses were performed on samples obtained before treatment initiation and at the four-month follow-up. At baseline, characteristic up regulation of mRNAs encoding pro-inflammatory mediators, including TNF-α, LTA, CRP, IL-1A and IL-17C was observed in PBL from the patient (Table 1). In addition, these cells expressed high levels of mRNAs encoding chemokines (IL-8, CCL1, CCL7, CCL8, CCL16, CCL24, CCL26, and CXCL5) or their receptors (XCR1, CCR2, CCR6, CCR8, and CCR9). In contrast, the expression of genes encoding CD40 Ligand (CD40L), IFN-α, IL-22, CXCL2 and CXCL14 was not detected. High levels of the pro-inflammatory cytokines IL-1β, IL-6, IL-8 and IL-10 were detected in the supernatant following 48 h incubation of PBLs in culture medium alone, while comparatively low levels of IFN-γ and TNF-α were found. On the contrary, IFN-α, IL-4 or IL-5 were not detected in cell supernatant (Table 2).
Table 1

Gene expression profile in a patient with chikungunya virus infection before and four months following methotrexate (MTX) treatment.

Gene NameUnigene IDDescriptionBefore MTX Fold/ControlAfter MTX Fold/ControlBefore/after Fold ††
Inflammatory mediators

TNF-α241570Tumor necrosis factor-α (TNFsuperfamily, member 2)9†-15-135

LTA36Lymphotoxin alpha (TNF superfamily, member 1)1-10-13

CRP76452C-reactive protein, pentraxin-related12-3-33

IL-1A1722Interleukin 1, alpha2-5-9

IL-1F5516301Interleukin 1 family, member 5 (delta)841-90

IL-1F6278910Interleukin 1 family, member 6 (epsilon)2-9-20

IL-1F7166371Interleukin 1 family, member 7 (zeta)4-3-11

IL-1F8278909Interleukin 1 family, member 8 (eta)7-4-28

IL-1F9211238Interleukin 1 family, member 98-2-20

IL-1RN81134Interleukin 1 receptor antagonist49-3-167

IL-9960Interleukin 93-6-20

IL-9R406228Interleukin 9 receptor5-3-15

IL-17C278911Interleukin 17C101-10

SPP1313Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)7-2-15

C3529053Complement component 312.25191

Th2-related factors

IL-13845Interleukin 135-11-55

IL-22287369Interleukin 22OFFOFF--

CD40L592244CD40 ligand (TNF superfamily, hyper-IgM syndrome)OFFOFF--

Inflammatory chemokines and their receptors

IFN-α211575Interferon-α2OFFOFF--

IL-8624Interleukin 851-5

XCR1248116Chemokine (C motif) receptor 134-2-62

CCL172918Chemokine (C-C motif) ligand 14-31-109

CCL7251526Chemokine (C-C motif) ligand 73-14-40

CCL8271387Chemokine (C-C motif) ligand 82-46-80

CCL1610458Chemokine (C-C motif) ligand 166-3-22

CCL24247838Chemokine (C-C motif) ligand 2476-3-190

CCL26131342Chemokine (C-C motif) ligand 267-2-15

CCR2644637Chemokine (C-C motif) receptor 213897

CCR646468Chemokine (C-C motif) receptor 64-5-17

CCR8113222Chemokine (C-C motif) receptor 88-2-19

CCR9225946Chemokine (C-C motif) receptor 95-3-15

CXCL2590921Chemokine (C-X-C motif) ligand 2OFF2ON

CXCL589714Chemokine (C-X-C motif) ligand 5274-7

CXCL14483444Chemokine (C-X-C motif) ligand 14OFF1ON

Patient had persistent specific IgM antibodies and erosive arthritis for two years before treatment.

† gene expression in patient peripheral blood mononuclear cells compared to those observed in cells from three healthy controls using real-time RT-PCR. Results shown as fold expression compared to control values. Inflammatory arrays were performed using RT2 Profiler PCR Array System (Ref: APHS-011B, SuperArray, Frederick, USA, http://www.superarray.com

†† Comparison of gene expression before MTX treatment and following 4 months therapy

Table 2

Cytokine profiles from patient peripheral blood mononuclear cell supernatants before and four months following methotrexate (MTX) treatment.

pg/ml

Patient cells††
CytokineHealthy controlsBefore MTXAfter MTX
IFN-γ0-1013<10

IL-1β0-101 1002

IL-60-359 482864

IL-8150-20001 47951094

IL-100-104254

TNF-α0-6092<10

† Cytokine levels in supernatants from cells incubated 48 h in medium alone and quantified using FlowCytomix Human Th1/Th2 Kit as recommended (Bender Medsystems, Vienna, Austria, http://www.bendermedsystems.com).

†† No cytokine was detected in serum. IFN-α, IL-2, IL-4, IL-5 and IL-12 were not detected in these samples.

Gene expression profile in a patient with chikungunya virus infection before and four months following methotrexate (MTX) treatment. Patient had persistent specific IgM antibodies and erosive arthritis for two years before treatment. † gene expression in patient peripheral blood mononuclear cells compared to those observed in cells from three healthy controls using real-time RT-PCR. Results shown as fold expression compared to control values. Inflammatory arrays were performed using RT2 Profiler PCR Array System (Ref: APHS-011B, SuperArray, Frederick, USA, http://www.superarray.com †† Comparison of gene expression before MTX treatment and following 4 months therapy Cytokine profiles from patient peripheral blood mononuclear cell supernatants before and four months following methotrexate (MTX) treatment. † Cytokine levels in supernatants from cells incubated 48 h in medium alone and quantified using FlowCytomix Human Th1/Th2 Kit as recommended (Bender Medsystems, Vienna, Austria, http://www.bendermedsystems.com). †† No cytokine was detected in serum. IFN-α, IL-2, IL-4, IL-5 and IL-12 were not detected in these samples. Four months following initiation of treatment, the expression of most of the above mRNAs was attenuated, and expression of CD40L, IFN-α and IL-22 remained undetectable. At this time, cytokine levels measured in the cell culture supernatant were markedly decreased and surface CD40L expression on peripheral blood cells could not be detected (data not shown).

Conclusions

Chikungunya virus infection is usually a self-limiting disease characterized by arthralgia with late peripheral joint pain in the smaller joints [11,12]. A sole case of late articular destruction after decades of post CHIKV-chronic rheumatism has been reported with a questionable relationship to the CHIKV infection [9]. Our case is remarkable for the clearly erosive arthritis pattern accompanied with enthesopathies, which developed within less than two years of the index CHIKV infection [13]. The patient was positive for HLA B27 antigen although no clinical rheumatologic manifestations had been noted before the CHIKV infection. For this reason, we can conclude that he developed a form of spondylarthropathy. Concerning the acute phase, recent findings suggested that both classical and severe symptoms of chikungunya disease closely reflect CHIKV tissue tropism [14], with fibroblasts being the primary targets, as they are for other alphaviruses [1,15]. The molecular basis of this tropism may combine specific interactions between virus and host cells and tissues, and an intrinsic lower ability of this cell type to control CHIKV infection [8,14]. The pathogenesis of persistent arthritis remains unclear although persistent infection of synovial macrophages has been documented for other alphaviruses [16,17]. Moreover, factors secreted by infected macrophages seem to play a pivotal role in joint inflammation [18]. To date, the presence of CHIKV RNA in joints during the acute phase of infection has only been demonstrated in animal models [14,19]. CHIKV RNA has never been detected in joint tissues during the late phase, although it has been found in human muscle satellite cells three months after infection [2]. Taken together with reports of the presence of long lasting IgM anti-CHIKV antibodies [20], these findings could indicate the persistence of CHIKV in certain host tissues or cells. However, there is no evidence that viral persistence is necessary to sustain chronic joint pathology after the infection. In our case, an antigen-specific immunopathology may underlie the development of chronic joint disease due to the presentation of specific autologous or microbial arthritogenic peptides [21]. This would be consistent with the notion of an infectious trigger for immune activation derived from molecular mimicry which has been postulated as a potential pathogenic mechanism in autoimmunity [22-24]. High levels of pro-inflammatory cytokines IL-1, IL-6 and IL-8 were detected in cell supernatants from the patient's lymphocytes and elevated expression of genes encoding a variety of cytokines and chemokines known to be implicated in the pathogenesis of arthritis were also observed [25,26]. In contrast, IFN-α, IL-4 and IL-5 were not detected in cell supernatants whereas IL-10 was increased. Of interest, the lymphocytes failed to express genes encoding IFN-α, IL-22 and CD40L, which are required for B cell differentiation, optimal immunoglobulin isotype switching and antiviral activity. Although the persistence of specific IgM antibodies has been documented after CHIKV infections [20], an association between these antibodies and disease severity has not been established. It is possible that antibody persistence may be determined by the persistence of virus in host tissues since, in acute arboviral infections, IgM are generally no longer detectable after 6-12 months. Unfortunately, in our case, it was not possible to perform RT-PCR for detection of CHIKV in synovial fluid or tissue Viruses have evolved a number of mechanisms for suppressing host immune responses. In particular, viral proteins may suppress the retinoic acid-inducible gene I-like helicase and Toll-like receptor pathways important for the expression of type 1-IFNs, such as IFN-α isoforms, which play a crucial role in eliminating viral infections [14,27-29]. Immunoglobulin class switching from IgM to IgG and IgA is central to immunity against viruses and requires the activation of B-cells by T-cells via cytokine interactions with CD154/CD40L. Mutations in the CD40L gene have been observed in cases of inherited hyper-IgM X-linked immunodeficiences [27]. In this context, CHIKV may be able to evade T-cell dependent IgG and IgA responses by attenuating CD40L gene expression. Such a mechanism has been postulated previously to explain hyper IgM syndrome associated with various viral infections [30-32]. We report here a case of CHIKV infection with joint and bone erosion and persistent specific IgM nearly two years following infection. Transcriptomic and protein analysis revealed individual genes which could be implicated in the pathogenesis of chronic arthritis; these genes have not been associated previously with alphavirus-induced arthritis.

Consent

The patient has provided written consent to the use of his history for publication

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DMa took care of the patient. DMa and KE drafted the manuscript. BA and HT performed immunoglobulin assays. MMM, DMoy, DMa, JR and DMos performed the immunological analyses and evaluation. All authors reviewed the manuscript, contributed to its finalisation and approved the submitted version.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/9/200/prepub
  32 in total

Review 1.  Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells.

Authors:  Antal Rot; Ulrich H von Andrian
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

2.  Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism.

Authors:  K D Ryman; W B Klimstra; K B Nguyen; C A Biron; R E Johnston
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  Type I interferons in host defense.

Authors:  Daniel B Stetson; Ruslan Medzhitov
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

4.  Infectious diseases. Massive outbreak draws fresh attention to little-known virus.

Authors:  Martin Enserink
Journal:  Science       Date:  2006-02-24       Impact factor: 47.728

Review 5.  The pathogenetic role of HLA-B27 and its subtypes.

Authors:  Muhammad Asim Khan; Alessandro Mathieu; Rosa Sorrentino; Nurullah Akkoc
Journal:  Autoimmun Rev       Date:  2006-12-08       Impact factor: 9.754

6.  Chikungunya viral arthropathy: a clinical description.

Authors:  A C Kennedy; J Fleming; L Solomon
Journal:  J Rheumatol       Date:  1980 Mar-Apr       Impact factor: 4.666

7.  Rheumatoid arthritic syndrome after chikungunya fever.

Authors:  E D Fourie; J G Morrison
Journal:  S Afr Med J       Date:  1979-07-28

8.  A destructive arthropathy following Chikungunya virus arthritis--a possible association.

Authors:  S W Brighton; I W Simson
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

Review 9.  Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses.

Authors:  Andreas Suhrbier; May La Linn
Journal:  Curr Opin Rheumatol       Date:  2004-07       Impact factor: 5.006

10.  Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period.

Authors:  Daouda Sissoko; Denis Malvy; Khaled Ezzedine; Philippe Renault; Frederic Moscetti; Martine Ledrans; Vincent Pierre
Journal:  PLoS Negl Trop Dis       Date:  2009-03-10
View more
  39 in total

Review 1.  Management of chikungunya arthritis.

Authors:  J Kennedy Amaral Pereira; Robert T Schoen
Journal:  Clin Rheumatol       Date:  2017-08-03       Impact factor: 2.980

2.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

3.  A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.

Authors:  Thomas E Morrison; Lauren Oko; Stephanie A Montgomery; Alan C Whitmore; Alina R Lotstein; Bronwyn M Gunn; Susan A Elmore; Mark T Heise
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 4.  Recent Advances in Dengue: Relevance to Puerto Rico.

Authors:  David H Noyd; Tyler M Sharp
Journal:  P R Health Sci J       Date:  2015-06       Impact factor: 0.705

5.  Clinical Manifestations Associated with Peripheral Joint Involvement in Patients with Acute Chikungunya Virus Infection.

Authors:  Mariangelí Arroyo-Ávila; Amanda Cabán; Enid J García-Rivera; Marisela Irizarry-Pérez; Hilda Torres; Héctor Gorbea; Luis M Vilá
Journal:  Am J Trop Med Hyg       Date:  2017-01-30       Impact factor: 2.345

Review 6.  Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Authors:  Laurie A Silva; Terence S Dermody
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

7.  Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.

Authors:  Weiqiang Chen; Suan-Sin Foo; Adam Taylor; Aleksei Lulla; Andres Merits; Linda Hueston; Mark R Forwood; Nicole C Walsh; Natalie A Sims; Lara J Herrero; Suresh Mahalingam
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

8.  An essential role of antibodies in the control of Chikungunya virus infection.

Authors:  Fok-Moon Lum; Teck-Hui Teo; Wendy W L Lee; Yiu-Wing Kam; Laurent Rénia; Lisa F P Ng
Journal:  J Immunol       Date:  2013-05-13       Impact factor: 5.422

9.  Critical role for bone marrow stromal antigen 2 in acute Chikungunya virus infection.

Authors:  Wadie D Mahauad-Fernandez; Philip H Jones; Chioma M Okeoma
Journal:  J Gen Virol       Date:  2014-07-22       Impact factor: 3.891

10.  A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.

Authors:  Shirley Lam; Min Nyo; Patchara Phuektes; Chow Wenn Yew; Yee Joo Tan; Justin Jang Hann Chu
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.